Headerimage K. PH: Infection & High Altitude

K. PH: Infection & High Altitude

PH associated with infectious diseases and high altitude

Research Area Leaders

Prof. Dr. H. Ardeschir Ghofrani

  • Dept. Internal Medicine
  • Medical Clinic II
    Klinikstrasse 33
    35392 Giessen
  • Write E-Mail

Prof. Dr. Martin R. Wilkins

  • Dept. of Experimental Medicine2N7
  • Commonwealth Building
    Hammersmith Campus
    London, UK

Faculty involved

T. Braun, S. Dimmeler, H.A. Ghofrani, F. Grimminer, J. Lohmeyer, S.S. Pullamsetti, R.T. Schermuly, W. Seeger, N. Weissmann, M.R. Wilkins, A.M. Zeiher, L. Zhao



Area K is a novel initiative aimed at institutionalising and promoting collaborative research between the ECCPS, Imperial College London (ICL) and associated partners (Cambridge University, the global Pulmonary Vascular Research Institute; PVRI). Our goal is to pool resources to combat states of pulmonary hypertension (PH) which represent major public health problems in resourcepoor areas of the world. We will focus on three major diseases

  1. Schistosomiasis, which is the third leading endemic parasitic disease in the world, with >300 million infected individuals, 5-7% of which develop PH, which may progress even under antiparasitic treatment.
  2. Human immunodeficiency virus (HIV) infection (>40 million people affected worldwide, with >50 % in Sub-Saharan Africa) increases the risk for PH development >1000-fold, a statistic that remains unchanged even under combination antiretroviral therapy, and
  3. High altitude (HA)- PH. More than 140 million people live at an altitude of >2500 m, with up to 5 % of them developing chronic mountain sickness/PH. Studies will include molecular profiling and identification of signatures in diseased human and experimental lungs and cultured human lung cells (transcriptome, miRome, exome, proteome), hypothesis-generating and therapeutic studies in preclinical models, and genome-wide association studies. We aim to develop novel anti-inflammatory strategies for antiremodelling/prevention of PH, to decipher the molecular pathogenesis of Schistosoma mansoni (SM-PH) and HIV-induced PH (HIV-PH), to identify biomarkers for early bedside detection of SMPH and HIV-PH, to identify genes underlying susceptibility versus resistance to hypoxia and perform early clinical trials to combat SM-PH, HIV-PH and HA-PH in regions severely affected by these diseases.